J&J Ups Negotiation Dance With Guidant To Get Reduced Price After Recalls
Johnson & Johnson will need to weigh the risks of trying to renegotiate its $24 bil. acquisition of Guidant with its interest in entering the rapidly-expanding ICD market
Johnson & Johnson will need to weigh the risks of trying to renegotiate its $24 bil. acquisition of Guidant with its interest in entering the rapidly-expanding ICD market